EUVIMEDEUVIMED entdecken
Crossref

Multiplexing Homocysteine into First-Tier Newborn Screening Mass Spectrometry Assays Using Selective Thiol Derivatization

C Austin Pickens, Elya Courtney, Samantha L Isenberg, Carla Cuthbert, Konstantinos Petritis iD

Clinical Chemistry · 2023

DOI: 10.1093/clinchem/hvad007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Chemistry, 2023. Verfasst von C Austin Pickens und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, United States. Hauptthemen laut MEDLINE: Neonatal Screening, Homocystinuria. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Classical homocystinuria (HCU) results from deficient cystathionine β-synthase activity, causing elevated levels of Met and homocysteine (Hcy). Newborn screening (NBS) aims to identify HCU in pre-symptomatic newborns by assessing Met concentrations in first-tier screening. However, unlike Hcy, Met testing leads to a high number of false-positive and -negative results. Therefore, screening for Hcy directly in first-tier screening would be a better biomarker for use in NBS.

Methods

Dried blood spot (DBS) quality control and residual clinical specimens were used in analyses. Several reducing and maleimide reagents were investigated to aid in quantification of total Hcy (tHcy). The assay which was developed and validated was performed by flow injection analysis–tandem mass spectrometry (FIA-MS/MS).

Results

Interferents of tHcy measurement were identified, so selective derivatization of Hcy was employed. Using N-ethylmaleimide (NEM) to selectively derivatize Hcy allowed interferent-free quantification of tHcy by FIA-MS/MS in first-tier NBS. The combination of tris(2-carboxyethyl)phosphine (TCEP) and NEM yielded significantly less matrix effects compared to dithiothreitol (DTT) and NEM. Analysis of clinical specimens demonstrated that the method could distinguish between HCU-positive, presumptive normal newborns, and newborns receiving total parenteral nutrition.

Conclusions

Here we present the first known validated method capable of screening tHcy in DBS during FIA-MS/S first-tier NBS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neonatal ScreeningHomocystinuriaHumansInfant, NewbornTandem Mass SpectrometryQuality ControlFlow Injection AnalysisHomocysteine

Substanzen

Homocysteine

Autor:innen und Institutionen

  • Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA, United States.

ORCID-Profile: Konstantinos Petritis

Zitieren

APA

Pickens, C. A., Courtney, E., Isenberg, S. L., Cuthbert, C., & Petritis, K. (2023). Multiplexing Homocysteine into First-Tier Newborn Screening Mass Spectrometry Assays Using Selective Thiol Derivatization. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvad007

Vancouver

Pickens CA, Courtney E, Isenberg SL, Cuthbert C, Petritis K. Multiplexing Homocysteine into First-Tier Newborn Screening Mass Spectrometry Assays Using Selective Thiol Derivatization. Clinical Chemistry. 2023. doi:10.1093/clinchem/hvad007

BibTeX
@article{Pickens2023,
  author = {Pickens, C Austin and Courtney, Elya and Isenberg, Samantha L and Cuthbert, Carla and Petritis, Konstantinos},
  title = {Multiplexing Homocysteine into First-Tier Newborn Screening Mass Spectrometry Assays Using Selective Thiol Derivatization},
  journal = {Clinical Chemistry},
  year = {2023},
  doi = {10.1093/clinchem/hvad007}
}
Kostenlos starten →